The FDA Rejected Capricor's Duchenne Therapy and Called the Trial Data Unreliable
The FDA went beyond a routine rejection, publishing a statement that cites serious data integrity violations in Capricor's pivotal Duchenne trial. The company says it stands behind its data.












